Quantcast
Last updated on April 24, 2014 at 13:17 EDT

Latest Monoclonal antibodies Stories

2013-11-18 12:29:12

DALLAS, November 18, 2013 /PRNewswire/ -- The "Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018", provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global Biosimilars Market...

2013-11-14 12:26:27

Compared to One Year Ago, TNF-alpha Inhibitors Have Seen Growth in All Three Lines of Therapy, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has seen growth in all three lines of therapy, particularly the second- and...

2013-11-12 23:27:58

Monoclonal antibodies specific to Rift Valley Fever Virus developed by Maine Biotechnology Services, in partnership with the USDA-Agricultural Research Service, are now available for sampling. The antibodies were developed to support ongoing research efforts to advance adequate vaccine and rapid detection methods. Portland, Maine (PRWEB) November 12, 2013 In July 2012, Maine Biotechnology Services entered into a partnership with Dr. Scott McVey, supervisor of the USDA-Agricultural...

2013-11-12 23:25:17

Reportbuyer.com just published a new market research report: Psoriasis Treatment: World Drug Market 2013-2023. London (PRWEB) November 12, 2013 Report Details Psoriasis drugs - this new study shows you R&D, opportunities, and potential revenues What's the future of treating psoriasis? Visiongain's new report gives you revenue predictions from 2013, helping you stay ahead. There you see financial results, R&D trends, opportunities, and potential revenues. Avoid falling...

2013-11-07 23:34:32

A new randomized, controlled trial(RCT) is the fourth RCT to provide evidence for the efficacy of etanercept for intervertebral disc-related pain. The first human data regarding the effectiveness of etanercept for sciatica was reported by the Institute of Neurological Recovery more than a decade earlier. Los Angeles, California (PRWEB) November 07, 2013 A new randomized clinical trial (RCT) published in the November 1, 2013 issue of the journal Spine (1) provides new evidence for the...

2013-11-07 23:30:39

RnRMarketResearch.com adds Latest Report on “Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth” to its store. Dallas, TX (PRWEB) November 07, 2013 The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of...

2013-11-07 08:32:43

SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that data from its ongoing Phase 1 trial of KB004, an anti-EphA3 monoclonal antibody (mAb), will be presented at a poster session at the 55(th) American Society of Hematology (ASH) Annual Meeting and Exhibition. The Phase 1 trial of KB004 is a multi-center, dose-escalation study evaluating KB004 in patients with advanced hematologic malignancies. The presentation will...

2013-11-05 08:34:27

SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has entered into an antibody and vaccine development collaboration with The Scripps Research Institute (TSRI) of La Jolla, CA. Under the terms of the agreement, Sorrento obtains an exclusive, worldwide license to TSRI's novel technologies based on ghrelin signaling inhibition for the prevention and treatment of obesity and other metabolic disorders. A research group...

2013-11-04 04:21:58

BREDA, The Netherlands and GHENT, Belgium, November 4, 2013 /PRNewswire/ -- arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). Under the terms of the agreement, the parties will closely collaborate to use arGEN-X' SIMPLE Antibody(TM) technology in validating the biology of a novel cancer immunomodulation target and creating functional leads with therapeutic potential. arGEN-X has an option to develop and commercialize...

2013-10-31 12:27:22

-- Results presented as late breaker at American College of Rheumatology -- LAKE FOREST, Ill., Oct. 31, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, this week shared the results of two open-label extension studies of CT-P13 (infliximab), one in patients with rheumatoid arthritis, the other in patients with ankylosing spondylitis, which were presented at the 2013 American College of Rheumatology (ACR)/Association of...